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Despite advances in the treatment of cancer, recurrence and
metastasis continue to pose major problems in clinical man-
agement. The relationship between circulating tumour cells
and the development of secondary disease is not fully under-
stood. However, a method to detect small numbers of such
cells may provide a tool with which to evaluate their role in
the disease process, and by implication the possible benefits
of eliminating them. One area of convergence between
molecular biology and clinical cancer medicine has been in
the new methods for detecting systemic spread of tumour
cells.
Morphology, flow cytometry and conventional cytogenetics
have been used to detect circulating tumour cells at a level of
1 in 100, and the more sensitive method of immuno-
cytochemistry may detect one tumour cell in 105 normals
(Molino et al., 1991; Osborne et al., 1991). This technique is,
however, dependent upon the availability of antibodies to
tumour-associated cell-surface antigens and may be subject to
false positives when antibodies cross-react or tumour
antigens are presented on host immune cells (Heydermann
and McCartney, 1985).
The advent of the polymerase chain reaction (PCR) and
the ability to amplify a specific region of DNA between
defined oligonucleotide sequences using repeated cycles of
denaturation, annealing and extension has made an enor-
mous impact upon nucleic acid analysis (Saiki et al., 1986).
By amplification of tumour-specific sequences, the PCR has
been shown in a variety of studies to detect one malignant
cell in up to 107 normal cells (Mattano et al., 1992; Alkan et
el., 1993; Cross et al., 1993; Fabrega et al., 1993; Datta et al.,
1994; Gerhard et al., 1994; Negrin and Pesando, 1994). This
increases the sensitivity of detection by an order of mag-
nitude when compared with immunocytochemistry.
Studies of PCR amplification of tumour-specific DNA
sequences have been possible mainly in haematological
malignancies in which consistent and well-characterised
molecular abnormalities are present. For solid tumours such
abnormalities are uncommon and other strategies are
required. We and others have used the amplification of
tissue-specific RNA, after reverse transcription, as a marker
of solid tumour cells in the blood, thus avoiding the require-
ment for a DNA sequence abnormality (Smith et al., 1991;
Burchill et al., 1994a).
Methods
The choice of target for amplification is evidently determined
by the specific characteristics of the malignant cells. Genomic
DNA has considerable advantages since archival embedded
material can be studied and the extraction process is more
robust, but only somatic abnormalities in the tumour cells
may usefully be detected in this way. Specific oncogene muta-
tions in genomic DNA may be used to identify malignant
cells, although artefactual results owing to errors in poly-
merisation may complicate the interpretation. To detect low
copy numbers of such mutations, mutant-specific primers are
necessary to give adequate sensitivity.
Messenger RNA is an increasingly used target for the
detection of tumour cells, after production of complementary
DNA by reverse transcription (RT-PCR) (Veres et al.,
1987). This allows the detection of translocations and other
rearrangements which occur within introns as well as pro-
viding some tissue specificity according to the genes tran-
scribed in particular cells. The principal limitation to the use
of wild-type gene expression for the detection of tumour cells
is obviously that the gene should not normally be expressed
in peripheral blood cells (or bone marrow or lymph nodes if
these are the tissues studied). To study the expression of
genes it is important to amplify selectively cDNA produced
from the RNA and not contaminating genomic DNA.
Removing all DNA from extracted RNA samples can be a
problem. Treatment with RNAse-free DNAse and the inc-
lusion of reverse transcriptase negative controls is essential to
confirm the specificity of amplification from RNA. Where
possible, primers should be selected to span an intron, result-
ing in the synthesis of different-sized amplification products
from the spliced RNA and any contaminating genomic
DNA.
The occurrence of false-positive results is a difficulty which
is born of the immense power of the technique. The smallest
amount of contamination may yield a spurious result, a more
difficult problem when there is no distinction in size between
the products from different individuals. Only scrupulous
attention to laboratory practice and the physical separation
of nucleic acid extraction, PCR amplification and the mani-
pulation of amplicons will prevent this (Kwok and Higuchi,
1989).
Unlike more traditional methods of detection, the PCR is
difficult to quantitate in a way which yields information
about the numbers of positive cells in the population. The
paucity of quantitative information has to some extent
limited the prognostic power of the technique. The methods
devised for quantitation include the addition of different-
sized competitor target molecules (Fukuhara et al., 1992;
Cross et al., 1993; Meijerink et al., 1993) or the use of serial
dilutions (Brisco et al., 1994). The first method makes the
assumption that the kinetics of primer/DNA associations is
linear in a variety of target/competitor ratios. Although serial
dilution of samples is more laborious, comparison of
amplification over a range of RNA or DNA concentrations
for a target gene compared with a control gene is more
reliable providing analysis is made over the exponential range
of amplification. However, semi-quantitation of RT-PCR in
this way does not allow clear statements regarding tumour
cell numbers since the copy number and transcription rate of
individual tumour cells will vary between individuals. As with
all methodologies, sampling errors assume increasing impor-
tance as target cell numbers decline. The RT-PCR in partic-
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13 March 1995ular may be susceptible to failure when transcription is
temporarily down-regulated owing to chemotherapy, despite
the continued presence of tumour cells.
Increased sensitivity of detection may be achieved by
Southern blotting and hybridisation using an oligonucleotide
probe to sequences within the amplified segment. This has
the advantage ofconfirming the specificity of the PCR. Alter-
natively, direct sequencing can be carried out, which may be
particularly useful where individuals have unique break-
points.
Enrichment of samples for tumour cells is a strategy which
may become more widespread in the future. Improved
immunomagnetic methods of cell sorting make it possible to
select for tumour surface antigens before extracting nucleic
acids, reducing the amount of background material (Hard-
ingham et al., 1993).
Malignancies studied
Haematological malignancy
Immunoglobulin and T-cell receptor gene rearrangements
Valuable information has been obtained in lymphoid malig-
nancies by amplification of clonally rearranged immuno-
globulin and T-cell receptor genes. The primers used are
complementary to the framework segments of the immuno-
globulin variable regions and the consensus joining region for
B-cell clones, and the variable and joining regions of the '-
and 6-receptors for T cells. Inevitably, several sets of primers
must be tested for each patient in order to determine the
most suitable targets. Although the presence of competing
polyclonal populations restricts the sensitivity of this method
for residual disease, sequencing of the clonal rearrangement
and the subsequent use of patient-specific primers can im-
prove this (Potter et al., 1992; Nizet et al., 1993). The techni-
que is finding increasing application in the analysis of haemo-
poietic progenitor cell harvests used to restore the bone
marrow after myeloablative therapy. Initial results in multi-
ple myeloma suggest that peripheral blood progenitor cells
often contain populations with clonal IgH rearrangements,
although it is not clear whether these contribute to recurrence
rates (Dreyfuss et al., 1993; Bird et al., 1994). The rational
development of in vitro treatments for these harvests by
methods such as CD34+ cell selection or immunomagnetic
'purging' will depend upon these analyses for proof of
efficacy.
The study of PCR for immunoglobulin and T-cell receptor
gene rearrangements has been successfully applied to lym-
phoblastic leukaemia (ALL) (Yamada et al., 1990). Several
groups have demonstrated that the approach is feasible, with
up to 90% of childhood ALL patients having amplifiable
clonal markers (Steward et al., 1994). In one study of 152
patients, those with a monoclonal band still detectable fol-
lowing induction therapy showed a 57% recurrence rate as
compared with 25% for those in whom only polyclonal
products were seen. (Brisco et al., 1993). Other smaller
studies have confirmed the relationship between recurrence
rate and PCR positivity (Neale et al., 1991; Nizet et al.,
1993), a relationship which appears to hold for quantitative
estimations of the number of residual leukaemic blasts
(Brisco et al., 1994). The rate of decline of clonal cell
numbers during treatment has also been shown to correlate
with the probability of recurrence in some small studies
(Nizet et al., 1993; Cave et al., 1994). Unfortunately, there is
also a low but definite recurrence rate even for those in
whom no clonal population can be identified, possibly owing
to clonal evolution (Langlands et al., 1993; Steward et al.,
1994).
Bcl-2/immunoglobulin gene translocations One of the best-
characterised chromosomal rearrangements associated with
lymphoma is the t(14;18)(q32;q21), seen particularly in fol-
licular types, which juxtaposes the apoptosis-suppressing bcl-
2 gene with the immunoglobulin heavy-chain genes (Cleary et
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al., 1986a). This translocation is readily detected in genomic
DNA using primers complementary to the immunoglobulin
joining region consensus and sequences within the major
breakpoint region and minor cluster region respectively
(Cleary et al., 1986b; Lee et al., 1987; Crescenzi et al., 1988).
The variety of breakpoints within small clusters, together
with the variable insertion of 'N' regions or even fragments
ofdiversity region chromatin (Cotter et al., 1990), results in a
considerable size range of amplified PCR products, so that
the individual t(14;18) clones may be identified by separation
on agarose gels. Sequence analysis has shown that the break-
point is rarely, if ever, the same in two clones (Bakshi et al.,
1987; Cotter et al., 1990; Johnson et al., 1994).
The significance of the detection of cells carrying the
t(14;18) is uncertain. Some studies have demonstrated trans-
locations in non-malignant lymphoid tissue (Limpens et al.,
1991; Aster et al., 1992) and even normal blood donors
(Limpens et al., 1992), while the lymphoma-associated clone
may be detected in the blood of patients in remission for
several years aher both conventional (Price et al., 1991a;
Finke et al., 1993) and myeloablative therapy (Johnson et al.,
1994). There are certainly some data to suggest that failure to
remove t(14;18)-bearing cells from autologous bone marrow
harvests is associated with earlier recurrence following their
use for haemopoietic rescue (Gribben et al., 1991), although
this has not been confirmed in other studies (Johnson et al.,
1994). Despite the uncertainty regarding the presence of
translocation-bearing cells in prolonged remission, the intui-
tive suggestion that patients are more likely to remain disease
free if the clone is eliminated seems to be supported by some
data. Patients with PCR-positive bone marrow during follow-
up after myeloablative treatment have earlier recurrences
(Gribben et al., 1993), although the relationship is less clear
in peripheral blood (Gribben et al., 1994). New
immunotherapeutic strategies are now being implemented to
treat such patients on the basis of PCR results (Grossbard et
al., 1993).
A variety of other chromosomal rearrangements which
have been described in lymphoma are detectable by PCR. All
require mRNA and a reverse transcription step. The trans-
locations described and the genes involved are shown in
Table I. The t(8;14), t(2;5) and t(3;14) are all amenable to
this approach, although the t(11;14)(ql3;q32) of centrocytic
lymphoma shows a scattering of breakpoints on chromosome
11 which makes the use of one set ofprimers inadequate. No
studies have yet been carried out using these rearrangements
as markers of disease although they have found some use in
diagnosis.
The Philadelphia chromosome One of the earliest transfers
from classical cytogenetics to molecular biology was the
identification of the BCR and ABL genes on either side of
the t(9;22)(q34;ql 1) in chronic myeloid leukaemia (CML)
and some cases of ALL. This translocation is now detectable
by RT-PCR using different sets of primers for the p190 and
p210 variants (Kawasaki et al., 1988). The PCR has been
used for monitoring patients with CML following treatment,
in particular myeloablative therapy and allogeneic bone mar-
row transplantation (Gabert et al., 1989; Morgan et al., 1989;
Roth et al., 1989; Sawyers et al., 1990). Detection of the
translocation over a year from the date of transplantation
has been shown to have adverse prognostic significance,
while patients who are initially PCR positive before 1 year
may often become PCR negative subsequently. In these cases
the prognosis is as good as for the consistently PCR-negative
group (Delage et al., 1991; Hughes et al., 1991; Cross et al.,
1993). The results in Philadelphia-positive ALL are less con-
clusive owing to the smaller numbers ofpatients studied. One
group has found some patients with no RT-PCR detectable
BCR-ABL sequences after myeloablative treatment, and the
few patients with durable remissions remain PCR negative
(Miyamura et al., 1992). Detection of BCR-ABL transcripts
precedes clinical recurrence, and further treatments such as
interferon aor donor leucocyte infusions given at this time
may prolong remission (Vanrhee et al., 1994).Molecular detecton of circulatng tumourcells
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Table I Chromosomal rearrangements in lymphoma amenable to PCR detection
Rearrangement Genes involved Lymphoma type Reference
t(14;18)(q21;q32) Bc1-2/Ig heavy chain Follicular Cleary et al. (1986a)
Crescenzi et al. (1988)
t(8;14)(q24;q32) c-Myc/Ig genes Burkitt's Pelicci et al. (1986)
t(2;8)
t(8;22)
t(2;5)(23;q35) NPM/Alk Large cell anaplastic Morris et al. (1994)
t(3;14)(q27;q32) Bc1-6/Ig heavy chain Diffuse large cell Baron et al. (1993)
t(ll;14)(q13;q32) Bcl-l/Ig heavy chain Centrocytic Williams et al. (1992)
Table II Chromosomal rearrangements in leukaemia amenable to PCR detection
Rearrangement Genes involved Leukaemia type References
t(9;22)(q34;ql1) BCR/Abl CML, ALL Kawasaki et al. (1988)
t(l5;17)(q22;q21) RAR-a/PML AML(M3) Biondi et al. (1992)
Castaigne et al. (1992)
t(8;21)(q22;q22) AML-I/ETO AML(M2) Downing et al. (1993)
Kozu et al. (1993)
t(6;9)(p23;q34) DEKICAN AML Soekarman et al. (1992)
t(l;19)(q23;p13) PbxJ/E2A Pre-B-ALL Hunger et al. (1991)
Izraeli et al. (1992)
Priveritera et al. (1992)
t(4;11)(q21;q23) MLL on 1 1q23 ALL/AML Gu et al. (1992)
t(9;11)(p22;q23) Often paediatric Tkachuk et al. (1992)
t(l1;19)(q23;p13) Sometimes secondary Downing et al. (1994)
Head et al. (1994)
Yamamoto et al. (1994)
Inv(16)(pl3;q22) CBFJ/MYHII AML (M4) Dauwerse et al. (1993)
t(l;14)(p34;ql1) TAL-1 T-ALL Chen et al. (1990)
The use of autologous haemopoietic rescue following high-
dose treatment is also being explored in CML and Philadel-
phia-positive ALL (McGlave et al., 1994). It may be possible
to collect t(9;22)-negativeperipheral blood progenitor cells if
leucapheresis is performed early during granulocyte colony-
stimulating factor (G-CSF)-stimulated recovery from cyclo-
phosphamide priming (Carella et al., 1993). Similarly, in vitro
culture of bone marrow may result in selection of t(9;22)-
negative stem cells (Udomsakdi et al., 1992; Fabrega et al.,
1993). Tumour cell contamination is a critical factor in both
these approaches, and RT-PCR has been used for rapid
determination of the quality of reinfused progenitors (Allieri
et al., 1992; Nagafuji et al., 1993).
Retinoic acid receptor gene translocations The characteristic
translocation of acute promyelocytic leukaemia (APML) is
the t(15;17)(q22;ql 1), which transposes the retinoic acid
receptor a and PML genes (de The et al., 1990). These have
been cloned and RT-PCR used to define at least three
isoforms, which have been used to monitor residual disease
at the end of therapy (Biondi et al., 1992; Castaigne et al.,
1992; Miller et al., 1992). The presence of different isoforms
complicates the PCR, requiring several sets of primers in
order to cover the different breakpoints involved (Chang et
al., 1992; Chen et al., 1992; Matsuoka et al., 1993). There has
been some suggestion that patients with translocations in
exon 3 of PML have a worse prognosis than those with
intron 6 breakpoints, but this is based upon a small number
of observations in patients treated with an unusual type of
chemotherapy (Huang et al., 1993).
Detection of the t(l5;17) translocation following treatment
is a strong indicator of poor prognosis, with recurrences
occurring in almost all cases. Those patients in whom the
translocation is not detectable after chemotherapy have a
high chance of cure (Lococo et al., 1992) and the transloca-
tion has not been detected in patients in long-term remission
(Diverio et al., 1993). The use of all-trans retinoic acid
(ATRA) alone does not eliminate the t(15;17) clone even
when the clinical response is rapid and apparently complete,
and all patients develop recurrent disease if no consolidation
chemotherapy is given (Miller et al., 1993). Conversely, the
initial use of ATRA in combination with chemotherapy
resulted in rapid disappearance ofthe t(15;17) in a small pilot
study (Laczika et al., 1994), giving hope that molecularly
guided therapy may be possible in the future.
AML1/ETO gene translocations A more recent finding is
that the breakpoints in acute myeloid leukaemias charac-
terised by the t(8;21) lie within a single intron of the AML1
gene on chromosome 21 and at identical positions in the
ETO gene on chromosome 8 (Downing et al., 1993; Kozu et
al., 1993). Ninety per cent of these cases are of M2 subtype
and are generally thought to carry a better than average
prognosis (Swirsky et al., 1984). The constant position of the
translocation makes it a good target for detection by RT-
PCR, and studies are in progress to examine its use as a
marker. One group has found persistence of the translocation
despite durable complete remissions in seven patients, two of
whom had undergone myeloablative therapy and autologous
bone marrow transplantation (Kusec et al., 1994). Further
studies are awaited to determine whether the translocation
really does persist in patients with durable remissions.
As in lymphoma, several consistent chromosomal rear-
rangements have been characterised at the molecular level in
acute leukaemias of various types, all ofwhich may in future
be used for the detection of residual disease by RT-PCR.
These are shown in Table 1I.
Solid tumours
The cytogenetics of solid tumours are considerably more
complex and less well defined than those of haematological
malignancy, hence there have been few opportunities to
apply PCR techniques to aid diagnosis or monitor disease
following treatment (Table III).
The best-characterised abnormalities in solid tumoursinvolve mutations of either oncogenes or tumour-suppressor
genes. A common problem in using such mutations as targets
for the PCR is the number of different mutation sites and
lack of consistency within tumour types. Thus mutations in
the p53 gene are found throughout the open reading frame,
and although 'hotspots' have been identified even these
extend over four exons. However, K-ras shows a relatively
restricted pattern of mutation in some diseases such as car-
cinoma of the pancreas (80% of cases) (Almoguera et al.,
1988) or colon (50%) (Vogelstein et al., 1988), and recent
reports suggest that the use of primers specific to codon 12
mutations may allow detection of tumour cells in pancreatic
juice or blood (Hardingham et al., 1993; Tada et al., 1993).
PCR followed by phage cloning and hybridisation with
radioactive probes has been used to detect ras mutations in
colorectal cancer cells in faeces (Sidransky et al., 1992) and
may be applicable to blood or bone marrow, particularly
where samples of the primary tumour are available to
confirm the mutation.
Ewing's sarcoma One rearrangement which has been char-
acterised is the t(ll;22)(q24;ql2), found in 85% of Ewing's
sarcomas, juxtaposing the FLI-1 and EWS genes (Zucman et
al., 1992). Although the translocation may be detected in
genomic DNA, RT-PCR has been the method of choice
owing to its increased reliability and the suggestion that
different transcripts may be more clinically informative than
detection of tumour cells alone (Delattre et al., 1994;
Zoubeck et al., 1994). The European Ewing's Sarcoma Study
Group is currently evaluating the value of this method in
practice.
In the absence of common consistent chromosomal abnor-
malities in solid tumours, other targets have been sought.
The most promising results have been seen with RT-PCR
detection of tissue-specific antigens or enzymes.
RT-PCR of tissue-specific genes The first tissue-specific
enzyme used as a molecular marker was tyrosinase, expressed
in pigmented cells as part of the melanin synthesis pathway.
Using nested RT-PCR it proved possible to detect one
melanoma cell in at least 105 normal cells, although the
sensitivity varied according to the levels of tyrosinase tran-
scription in the cell lines used for the experiments. An initial
study in seven patients with melanoma showed transcription
in the peripheral blood of four, while none was detected in
normal controls (Smith et al., 1991). Follow-up studies have
been less encouraging, with only three positives among 22
patients with metastatic melanoma (K Pittman et al., in
preparation) although recent data from nearly 300 patients
with melanoma showed a close correlation between clinical
disease stage and the frequency with which tyrosinase trans-
cription could be detected in the blood (Vormwald-Dogan et
al., 1994).
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Prostate-specific antigen (PSA) mRNA was identified in
the peripheral blood (Moreno et al., 1992) and lymph nodes
(Deguchi et al., 1993) of small numbers of patients with
prostate cancer but not in controls, with a level of sensitivity
that appeared better than immunocytochemistry. Further
refinement and increased sensitivity have been reported using
the recently cloned prostate-specific membrane (PSM) anti-
gen as a target (Israeli et al., 1994). The rate of detection
using nested RT-PCR for PSM appeared to be markedly
superior following radical prostatectomy, with 68% of
patients with negative PSA serology having positive PSM
results by PCR as compared with 3% for PSA. In view of
difficulties of interpretation for slightly raised levels of PSA
and the long natural history of asymptomatic prostate
cancer, it is difficult to know whether an increase in sen-
sitivity is likely to contribute usefully to management. The
use of such a marker following prostatectomy might be
predictive of recurrence, and it will be interesting to see
whether trials of hormonal therapy will confer benefit in this
setting.
Carcinoembryonic antigen (CEA) expression has been in-
vestigated as a marker of gastrointestinal and breast cancer.
RT-PCR for CEA was used to detect tumour cells in the
bone marrow of 14 of 21 patients, with dilution experiments
suggesting a level of sensitivity of 2-5 tumour cells in 107
normal cells (Gerhard et al., 1994). In 56 normal control
marrow samples no CEA expression was found, indicating
that other members of the CEA gene family expressed on
myeloid cells did not interfere. The sensitivity of tumour cell
detection by RT-PCR was greater than by immunocytology
for CEA or cytokeratins.
In neuroblastoma two different targets for RT-PCR have
been analysed. Expression of PGP-9.5, a protein related to
neurone-specific enolase (NSE), has been reported as a useful
marker (Mattano et al., 1992). The original report described
low levels of expression in normal peripheral blood and bone
marrow which did not appear to interfere with tumour cell
detection. However, a more recent study found levels of
PGP-9.5 expression in normal haemopoietic tissue sufficient
to exclude its usefulness as a marker (Norris et al., 1994).
Expression of tyrosine hydroxylase, the first enzyme in the
catecholamine synthesis pathway, has been used to detect
neuroblastoma cells in three separate studies. These have
shown tyrosine hydroxylase to be the target of choice for
examinations of bone marrow (Naito et al., 1991), peripheral
blood and peripheral blood progenitor cells (Burchill et al.,
1994a); Norris et al., 1994). Dilution experiments have dem-
onstrated detection of one tumour cell in 105 normal marrow
cells (Naito et al., 1991) or 1 in IO' normal blood cells
(Burchill et al., 1994a). No transcription of tyrosine hydrox-
ylase has been found in normal haemopoietic tissue. Studies
of blood samples from 23 patients showed some correlation
with clinical outcome: 13 of 23 presentation samples were
Table III Potential targets for detection of solid tumour cells in the circulation by
PCRI or RT-PCRb
Tumour type Target gene/antigen References
Pancreas/colon k-ras mutationa Sidransky et al. (1992)
Hardingham et al. (1993)
Tada et al. (1993)
Ewing's sarcoma t(I1;22)(q24;q12)b Zucman et al. (1992)
Delattre et al. (1994)
Prostate Prostate-specific antigenb Moreno et al. (1992)
Deguchi et al. (1993)
Breast/colorectal Carcinoembryonic antigenb Gerhard, et al. (1994)
Neuroblastoma PGP-9.5b Mattano et al. (1992)
Neuroblastoma Tyrosine hydroxylaseb Naito et al. (1991)
Burchill et al. (1994)
Melanoma Tyrosinaseb Smith et al. (1991)
Epithelial Cytokeratinsb Traweek et al. (1993)
Burchill et al. (1994)
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positive, 12 from patients with advanced disease. After
therapy all had become RT-PCR negative. Initial samples
from the remaining ten patients were negative and remained
so throughout treatment. Eight of ten samples obtained at
the time of disease recurrence were RT-PCR positive, the
two negative samples coming from patients with localised
deposits (Burchill et al., 1994b).
A number of studies have been performed to examine the
prognostic significance of epithelial antigen-bearing cells in
the lymph nodes, bone marrow and more recently peripheral
blood ofpatients with epithelial tumours. The earliest studies
examined expression of the epithelial membrane antigen
(EMA) in the bone marrow of breast cancer patients and
found a significant prognostic value with respect to disease-
free survival (Mansi et al., 1991). However, other studies
showed expression of the antigen upon haemopoietic cells
(Delsol et al., 1984; Heydermann and McCartney, 1985),
making interpretation of the results difficult. More recently,
the potential use of the cytokeratins (CKs) as markers for
tumours of epithelial origin has been investigated. These are
cytoskeletal intermediate filaments which are thought to be
expressed specifically in epithelial tissues on the basis of
immunohistochemical studies (Nagle, 1988). Cytokeratins 8,
18, 19 and 20 appear to have the greatest specificity in
immunostaining studies, some of which have also given prog-
nostic information according to the presence of cells in the
bone marrow or nodes (Schlimok et al., 1987; Cote et al.,
1991; Lindemann et al., 1992; Harbeck et al., 1994). How-
ever, none of the antibodies tested appears to be specifically
expressed, and the frequent finding of low levels of positive
staining among haemopoietic cells suggests that they may
detect antigen-presenting cells (Delsol et al., 1984). Using
RT-PCR, CK 8 and CK 18 are found in normal blood and
bone marrow, limiting their suitability as targets (Traweek et
al., 1993). The results for CK 19 are contradictory, with two
studies showing no transcription in normal blood samples
(Traweek et al., 1993; Datta et al., 1994) and another tran-
scription in 6 of 15 controls (Burchill et al., 1994c). The
presence of pseudogenes complicates the interpretation of
these results further (Savtchenko et al., 1988). Using nested
RT-PCR it was posible to detect one tumour cell in 105
normal cells, with 4 of 19 stage IV breast cancer patients
having detectable cells in the blood and five of six in the
bone marrow (Datta et al., 1994). In contrast, a study of CK
19 expression in lymph nodes found detectable transcription
in nodes from patients without cancer using nested primers,
although lowering the sensitivity by using single-round PCR
allowed distinction of malignant from normal specimens
(Schoenfeld et al., 1994). Transcription of CK 19 by normal
endothelium and fibroblasts may account for the difficulty in
interpreting lymph node results (Traweek et al., 1993). Cyto-
keratin 20 may prove to be a more useful target: it is found
in almost all cases of colorectal adenocarcinoma by immuno-
histochemistry (Moll et al., 1992), and thus far no transcrip-
tion has been detected in peripheral blood or bone marrow
samples by RT-PCR in 15 normal controls (Burchill et al.,
1994c). The value of epithelial cell tumour detection by
RT-PCR and its sensitivity compared with immunocyto-
chemical methods remain to be assessed in patient sam-
ples.
More recently described tumour antigens recognised by
cytotoxic T-cell clones such as the MAGE proteins (Boon et
al., 1992; Cox etal., 1994) may prove to be useful targets for
RT-PCR in the future. Expression of MAGE appears to be
confined to cells of the testis and a variety of tumour types
(Zakut et al., 1993). The disappearance from the circulation
of cells bearing the tumour antigen may well prove to be a
useful indicator of the success of immunological therapy aimed at modulating the T-cell response.
Future perspectives
The capacity to detect smaller and smaller numbers ofmalig-
nant cells does not inevitably translate into improved out-
come for those with the illnesses: the development of tumour
markers in small-cell lung cancer, for example, has made no
appreciable impact upon its poor prognosis. It is clear that
more effective treatment is required before the detection of
circulating tumour cells will affect the outcome for patients
with most forms of cancer. However, as new therapies evolve
so molecular information may be useful in monitoring their
impact.
The use of systemic therapy early in the course of malig-
nant illnesses ('adjuvant' therapy after surgery) has been
shown to influence survival in some common cancers, such as
those of the breast (Early Breast Cancer Trialists' Collabor-
ative Group, 1992) and colon (Moertel et al., 1990; Rieth-
muller et al., 1994). The improvements are, however, of
limited scale in a population of patients with relatively high
expectations oflong-term survival in any case. This results in
exposure of some patients to unnecessary toxicity as well as
making evaluation of the treatment difficult. The
identification ofspecific molecular markers may allow a more
rational allocation of such adjuvant therapy.
A similar consideration applies in the setting of haemato-
logical malignancy in which options for treatment
intensification or alternative approaches such as
immunological manipulation and the use of biological res-
ponse modifiers may be applicable. There is good evidence
that these newer strategies are most effective in patients with
disease in 'clinical remission' (Philip et al., 1987; Takvorian
et al., 1987; Price et al., 1991b; Hiddemann et al., 1994), but
clearly this also raises the difficulty of distinguishing those
with disease destined to recur and those likely to be cured. It
is in this field that molecular monitoring is most advanced
and that therapy is beginning to be designed accordingly.
Apart from the allocation of therapy to poor prognostic
groups, the molecular identification of residual disease may
also prove useful in determining surrogate end points. The
long natural history of many tumours makes the use of
survival or even time to recurrence a cumbersome means of
evaluating new adjuvant treatments, and the practical prob-
lem of continuing with ineffective therapy over long periods
may be more readily identified if reliable markers of tumour
persistence can be identified and applied.
The traditional practice of transferring treatments effective
in advanced disease to the adjuvant setting risks discarding
approaches which are specifically useful against microscopic
disease. While this may not be a major consideration in the
choice of cytotoxic chemotherapy, it seems very likely to be
critical in biological treatments such as immunological or
gene therapy. The use of molecular markers will be a useful
means of evaluating the potential of these new approaches in
clinical settings where they are most likely to be effective.
Another recent development is the increasing use of high-
dose chemotherapy, since the discovery of haemopoietic
growth factors has allowed the relatively easy collection of
autologous peripheral blood progenitor cells. The clinical
utility of this approach is still far from proven, with the
possible exception of high-grade non-Hodgkin's lymphoma,
and its application will depend upon two conditions. These
are the demonstration of a tumour-ablative as well as a
myeloablative effect, and the demonstration that the haemo-
poietic rescue is not also a means of reinfusing viable tumour
cells. The studies already conducted in lymphoma suggest
that neither of these will be easy to demonstrate, but the
application of molecular techniques may at least indicate
whether success is likely. The development of such techniques
should be a high priority before inappropriate use is made of
toxic and expensive treatments.
In summary, the PCR is increasingly used for the detection
of subclinical malignancy, allowing a redefinition of what
constitutes remission. Unfortunately, the low efficacy of
treatment for many malignancies makes such definitions
meaningless, but the development of new types of treatment
for use earlier in the illnesses will depend upon this approach.
What is needed now is a thorough assessment of the predic-
tive power of these techniques so that they can be applied to
the emergent therapies.Molculardetection ofcirculatingtumourcells
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